scholarly journals Contribution of traditional Chinese medicine combined with conventional western medicine treatment for the novel coronavirus disease ( COVID ‐19), current evidence with systematic review and meta‐analysis

2021 ◽  
Author(s):  
Fei Jiang ◽  
Nana Xu ◽  
Yanxi Zhou ◽  
Jinxing Song ◽  
Jinjuan Liu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Meta Analysis ◽  
Current Evidence ◽  
The Novel ◽  
Novel Coronavirus

scholarly journals A systematic review and meta-analysis of integrated traditional Chinese medicine and Western medicine in treating glomerulosclerosis

Medicine ◽  
2021 ◽  
Vol 100 (7) ◽  
pp. e24799
Author(s):  
Yue-tong Wang ◽  
Rong-qiang Zhang ◽  
Shu-fei Wang ◽  
Xian-cheng Li ◽  
Nan Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Meta Analysis

scholarly journals Efficacy and Safety of Traditional Chinese Medicine (Lianhua Qingwen) for Coronavirus Disease 2019: a Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
YongHong He ◽  
Li Qiang ◽  
SongPing Wang ◽  
Jun Deng ◽  
Lan Huan
Keyword(s):  
Systematic Review ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Western Medicine ◽  
Meta Analysis ◽  
Effective Rate ◽  
Controlled Trials ◽  
Disappearance Rate ◽  
Randomized Controlled ◽  
Cardinal Symptom

Abstract Background: The coronavirus disease 2019(COVID-19) had become an epidemic and spread across the world, lead to severe respiratory failure and death. Traditional Chinese Medicine(TCM), Such as Lianhua Qingwen has been widely used in the prevention and treatment of COVID-19, This systematic review and meta-analysis will assess the effects of traditional Chinese herbal medicine(Lianhua Qingwen) in COVID-19 pneumonia from the randomized controlled trials(RCTs) and case control studies(CCSs).Method: we search the literatures in databases inculding PubMed, Embase, Web of science, Cochrane Library, Wanfang, Chinese Science and Technology Periodical Database (VIP), Chinese Biomedical Literature Database (CBM) and China National Knowledge Infrastructure(CNKI), setting the date from December 1, 2019, to June 1, 2021, Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale were used to assess the quality of randomized controlled trials. All analyses were conducted by Stata 14.0.Results: nine studies with 1163 patients(616males) were included, six were RCTs, three are CCSs. Compared with patients treated by western medicine alone, patients treated by Lianhua Qingwen combined with western medicine have a higher overall effective rate[RR=1.20, 95%CI1.20(1.11, 1.31), P=0.000], cardinal symptom disappearance rate[disappearance rate of fever: OR:3.64, 95%CI(1.57, 8.47), P=0.001;disappearance rate of cough: OR:1.97, 95%CI(1.45, 2.68), P=0.001; disappearance rate of fatigue: OR:2.55, 95%CI(1.09, 5.99), P=0.032] and CT recovery rate[RR:1.25, 95%CI(1.13,1.38), P=0.000], reduce the rate of the progress into severe diseases of COVID-19 patients[RR:0.43, 95%CI(0.30, 0.62), P=0.000], with more shorter duration of fever[WMD=-1.07，95%CI(-1.77, -0.37), P=0.003], The including studies described that Lianhua Qingwen did not increase the adverse drug reactions.Conclusion: Lianhua Qingwen may have advantages in improving the clinical effective rate and cardinal symptom disappearance rate. Besides, it also had an excellent effect on the improvement of the chest CT and the proportion reducing of progress into severe clinical disease, which could be used as an effective therapy for COVID-19.

scholarly journals The Effect of Chinese Medicine Compound in the Treatment of Rheumatoid Arthritis on the Level of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Xuan Tang ◽  
Zehao Liu ◽  
Zhihua Yang ◽  
Shengmei Xu ◽  
Maojie Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chinese Medicine ◽  
Rheumatoid Factor ◽  
Western Medicine ◽  
Meta Analysis ◽  
Current Evidence ◽  
Cochrane Library ◽  
Cyclic Citrullinated Peptide ◽  
Citrullinated Peptide ◽  
Peptide Antibodies

Objectives: To evaluate the current evidence whether Chinese medicine compound (CMC) can reduce the serum levels of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP).Methods: We comprehensively searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), the Database for Chinese Technical Periodicals (VIP), and Wanfang data. We then performed a systematic review and meta-analysis of all randomized controlled trials (RCTs) assessing the CMC therapy methods. This study is registered with PROSPERO, number CRD42020216284.Results: In total, 65 studies were eligible for inclusion, including 6099 patients. The result of the meta-analysis showed that compared with common Western medicine therapy, CMC monotherapy or combined with Western medicine was able to reduce serum RF (SMD= −0.85, 95%CI −1.04 to −0.67) and anti-CCP (SMD= −0.56, 95%CI −0.79 to −0.32) levels to some extent. In the efficacy meta-analysis, a greater number of CMC-treated patients achieved the efficacy criteria after a period of treatment, where the relative risk (RR) was 1.20 [1.08, 1.33] for achieving ACR20, 1.57 [1.38, 1.78] for ACR50, and 2.21 [1.72, 2.84] for ACR70. At the same time, there was a statistically significant difference in the effective rate of the patient's TCM symptoms (RR = 1.22, 95%CI 1.19–1.26).Conclusions: Through this meta-analysis and systematic review, we found that CMC for the treatment of RA is effective in reducing RF and anti-CCP levels and might have better clinical efficacy than Western medicine monotherapy. Some active components are responsible for this efficacy and worth further exploring.

scholarly journals Traditional Chinese medicine for treating novel coronavirus (2019-nCoV) pneumonia: protocol for a systematic review and meta-analysis

2020 ◽  
Author(s):  
Yuxi Li ◽  
Xiaobo Liu ◽  
Liuxue Guo ◽  
Juan Li ◽  
Dongling Zhong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Meta Analysis ◽  
Grey Literature ◽  
Biomedical Literature ◽  
World Health ◽  
Cochrane Central Register ◽  
Academic Degree ◽  
Novel Coronavirus

Abstract Background: A new type of coronavirus, 2019 novel coronavirus (2019-nCoV), is causing an increasing number of cases of pneumonia and has been declared a Public Health Emergency of International Concern by the World Health Organization on 30 January 2020. The virus first appeared in Wuhan, China in late December 2019 and traditional Chinese medicine (TCM) is being used for its treatment. This systematic review and meta-analysis will assess studies of the effects of TCM in 2019-nCoV-infected pneumonia (NCIP).Methods: We will search electronic databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP) and Wanfang database using keywords related to NCIP and TCM. Reference lists of relevant trials and reviews will be searched. We will manually search grey literature, such as conference proceedings and academic degree dissertations, and trial registries. Two independent reviewers will screen studies, extract data and evaluate risk of bias. Data analysis will be conducted using Review Manager software (version 5.3.5) and R software (version 3.6.1).Discussion: This study will provide a high-quality synthesis of the effects of TCM for NCIP. The use of TCM for treatment or prevention of these novel viral infections affecting the respiratory tract will be investigated.Systematic review registration: PROSPERO registration number: CRD42020168004

Sign in / Sign up

Export Citation Format

Share Document